# A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

> **NCT05266196** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Salarius Pharmaceuticals, LLC** · enrollment: 10 (estimated)

## Conditions studied

- Ewing Sarcoma
- Myxoid Liposarcoma
- Desmoplastic Small Round Cell Tumor
- Extraskeletal Myxoid Chondrosarcoma
- Angiomatoid Fibrous Histiocytoma
- Clear Cell Sarcoma
- Myoepithelial Tumor
- Low Grade Fibromyxoid Sarcoma
- Sclerosing Epithelioid Fibrosarcoma

## Interventions

- **DRUG:** Seclidemstat

## Key facts

- **NCT ID:** NCT05266196
- **Lead sponsor:** Salarius Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-15
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266196, "A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05266196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*